Jeremy Chrisp – Founding CEO and Director of EpiAxis Therapeutics
Jeremy Chrisp is a biotechnology entrepreneur with extensive experience in the commercialisation of Australian technology, with a focus on business development and the management of early stage opportunities. Jeremy holds a PhD in physiology from the University of Canterbury (NZ) and is a Fellow of the Australian Institute of Company Directors (AICD). He has over thirty years experience in the Australian healthcare market, initially by working with leading global multinational companies, including Merck & Co, Stryker, Becton Dickinson & Medtronic.
Sudha Rao – Founder and Leader of Pre-Clinical Development
Sudha Rao is a Professor and Group Leader of the Gene Regulation and Translational Medicine Laboratory at the QIMR Berghofer Medical Research Institute, Brisbane, Australia. She is a domain expertise in epigenetics and cancer biology. Sudha completed her PhD at Kings College London prior to moving to industry, where she gained valuable drug development experience. This included the development of phase 1 and 2 assets in asthma, rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). Sudha was engaged by Aventis (now Sanofi) as a Senior Scientist for over 8 years before she was recruited to Australia to work under Professor Frances Shannon and later Professor Chris Parish at the Australian National University. More recently, she was recruited to the University of Canberra before joining QIMR Berghofer in late 2019.
There is a substantial unmet clinical need when it comes to fighting recurrent, metastatic breast cancer. This is the major cause of death in women with breast cancer. We aim to address that unmet need by the novel targeting of breast cancer stem cells, which are resistant to conventional systemic anticancer therapies and therefore contribute to the failure of these therapies in patients.
Professor Sudha Rao
Founder at EpiAxis Therapeutics